ClinicalTrials.gg
CompletedNCT03803579MASUpdated Jul 20, 2023

Baseline Concentration of Direct Oral Anticoagulant and Incidence of Adverse Event Measure And See (MAS)

An observational study in Atrial Fibrillation and Anticoagulant-induced Bleeding, sponsored by Arianna Anticoagulazione Foundation. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by Arianna Anticoagulazione Foundation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 252 studies in Atrial Fibrillation with a site in Italy — 44 open to participants now, 64 under way, 2 of them phase 3. Atrial Fibrillation · Italy.

Enrollment
16th of 95
2,000 · median 411
Started
2018
with 15 others
Observational
95 of 252
22 open now
Registered
131st of 252
by date

Among the 252 studies in Atrial Fibrillation with a site in Italy, this one is the 16th largest by enrollment of the 95 observational ones that give a count, is one of 16 that started in 2018, is one of 95 observational ones, and was the 131st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

44 of the 252 studies in Atrial Fibrillation with a site in Italy are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Atrial Fibrillation with a site in Italy, or all of them as a file.
02

Study summary

The MAS Study is an observational, multicentre, prospective cohort study in Non valvular Atrial fibrillation (NVAF) patients treated with one of the direct oral anticoagulants (DOACs) available in Italy for NVAF patients.

The general aim is to deepen the knowledge of DOAC treatment in NVAF patients, by measuring the plasma concentration of anticoagulant drugs and their correlation with any adverse events that may occur during treatment.

Read the detailed description

The MAS Study is an observational, prospective cohort study, double blind, multicentre, international and no Profit. Anticoagulation clinics, affiliated or not to the Italian FCSA, will be asked to take an active part in the study, provided they have the facilities for blood sampling and processing.

4000 consecutive NVAF outpatients, 1000 for each single drug, starting anticoagulation with one of the four DOAC (apixaban, dabigatran, edoxaban, rivaroxaban) will be enrolled at the moment of the first prescription. Patients will receive the type and dosage of DOAC on the base of clinical characteristics at the discretion of the attending physician, as the normal clinical practice, and the study will not influence the decision of the type and dosage of DOAC.

The primary study objective is to evaluate the possible relationship between DOAC anticoagulant levels at the trough, measured at steady state (within the first 2-4 weeks of treatment) and occurrence of bleeding and thromboembolic events during the subsequent one year follow up

03

Conditions studied

  • Atrial Fibrillation
  • Anticoagulant-induced Bleeding

Keywords

  • Atrial Fibrillation
  • Bleeding event
  • Thromboembolic event
  • Plasma concentration of drug
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

4000 consecutive Non Valvular Atrial Fibrillation outpatients, 1000 for each single drug, aged >18 years and starting anticoagulation with one of the four DOAC (apixaban, dabigatran, edoxaban, rivaroxaban) will be enrolled at the moment of the first prescription. Patients will receive the type and dosage of DOAC on the base of clinical characteristics at the discretion of the attending physician, as the normal clinical practice, and the study will not influence the decision of the type and dosage of DOAC

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • NVAF patients starting DOAC anticoagulation
  • age > 18 years
  • ability to give written
  • availability, as part of the normal withdrawals, to the blood sampling for the study purpose
  • availability for 12-months follow-up

Exclusion criteria

Exclusion Criteria:

  • age \< 18 years
  • indication for electrical cardioversion at the moment of drug prescription
  • participation in Phase II or III clinical trials
  • indication for treatment different from NVAF
  • not suitable to give or not giving
  • not available for blood collection or follow-up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Number and rate of major bleeding events and clinically relevant bleeds (defined according to International Society on Thrombosis and Haemostasis guidelines)

    Fatal bleeding; Acute clinically overt bleeding;intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal will be recorded in all patients.

    Time frame: From date of enrollment until the date of first documented event assessed up to 12 months

  2. Number and rate of patients with confirmed thromboembolic and thromboembolic-related dath

    Cardiovascular event: transient ischemic attack, stroke. myocardial infarction; the occurrence of deep vein thrombosis with or without pulmonary embolism will be recorded in all patients.

    Time frame: From date of enrollment until the date of first documented event assessed up to 12 months

  3. Number and rate of death patients (overall mortality)

    Cardiovascular related death; thromboembolic related dath, bleeding-related death, cancer related death will be recorded in all patients

    Time frame: From date of enrollment until the date of first documented event assessed up to 12 months

  4. Through plasma concentration (ng/ml) of Apixaban, Dabigatran, Edoxaban and Rivaroxaban

    Blood sampling is performed at trough level for each anticoagulant drug used after the last dose intake of dabigatran, apixaban, rivaroxaban and edoxaban

    Time frame: 15-20 days after the enrollment

Secondary outcomes

  1. Number and rate of patients who discontinued treatment

    The treatment withdrawal, either for patients or for physician decision-making will be recorded in all patients

    Time frame: From date of enrollment until the date of first documented event assessed up to 12 months

07

Study locations

1 site
  • Sophie Testa
    Cremona, 26100, Italy
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in May 2022, 45 months.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 45 months is close to that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2019
First posted
Jan 14, 2019
StartActual
Aug 9, 2018
Primary completionActual
May 30, 2022
CompletionActual
May 30, 2023
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03803579
Lead sponsor
Arianna Anticoagulazione Foundation
Responsible party
Sponsor
First posted
Jan 14, 2019
Start date
Aug 9, 2018
Primary completion
May 30, 2022
Completion
May 30, 2023
Last update
Jul 20, 2023

Study contacts

Sophie Testa, MD
study director · UUOO Lab Analisi Chim Cliniche Microb-Centro Emostasi, ASST-Cremona Italy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion